126 results about "Activating macrophage" patented technology

The invention relates to a method of treating or monitoring / diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formulaAb−Xwhere the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring / diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-β antigen and is produced from a clone resulting from immunization with an FR-β expressing B300-19 cell. The FR-β monoclonal antibody of the present invention specifically reacts with the FR-β antigen of activated macrophages and FR-β expressing leukemia cells and a therapeutic agent of the present invention contains an FR-β antibody immunotoxin which causes apoptosis in activated macrophages and FR-β expressing leukemia cells, as an active ingredient. Further, suitable administration form for the therapeutic agent of the present invention includes intravenous injection as well as joint injection in the case of therapeutic agents for rheumatoid arthritis and juvenile arthritis.

The invention relates to a method of treating or monitoring / diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring / diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

The invention relates to a CD47 and PD-L1 targeting bifunctional fusion protein, belongs to the field of biomedicine, and solves the problems that anti-PD-1 / PD-L1 treatment is poor in a low-immunogenicity tumor treatment effect and anti-CD47 treatment is poor in a targeting ability. The fusion protein is composed of a CD47 binding part and a PD-L1 binding part which are linked by a disulfide bond, can block the binding of CD47 and SIRPalpha, can block the binding of PD-L1 and PD-1, can achieve the effects of activating macrophages to phagocytize tumor cells and promoting antigen presentation in natural immunity, can achieve an effect of promoting the activation of tumor specific T cells in acquired immunity, and has lower blood toxicity; and as compared with the single use of anti-PD-L1 or anti-CD47 for treatment, the fusion protein has better antitumor curative effects and blood safety.

The invention relates to a method of identifying / monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand.

The invention relates to methods of detecting active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. In one embodiment, plaques that block from about 2% to about 60% of the lumen of a blood vessel can be detected.

The invention relates to a method of treating lupus erythematosus. In one embodiment, the method comprises the step of administering to a patient suffering from lupus erythematosus an effective amount of a composition comprising a conjugate or complex of the general formula L-X where the group L comprises a ligand capable of binding to activated macrophages or other stimulated immune cells, and the group X comprises an immunogen, a cytotoxin, or another compound capable of altering macrophage function. In another embodiment, the method comprises the step of administering to a patient suffering from lupus erythematosus an effective amount of a composition comprising a conjugate of the general formula L-X where the group L comprises a vitamin, or a vitamin-receptor binding analog or derivative thereof, and the group X comprises an immunogen, a cytotoxin, or another compound capable of altering macrophage function.

The invention discloses a genetic recombinant fusion protein. Tumors can be eliminated through two mechanisms, one mechanism refers to blockage of inhibitory signals for tumor-cell-induced macrophage, and the other mechanism refers to direct activation of the phagocytosis of the macrophage. The protein (SIRPalphaD1-Fc (signal-regulatory proteins alpha D1-Fc)) is formed by connecting human SIRPalphaD1 (a first Ig sample region of an outer membrane end of SIRPalpha) with an Fc segment of human IgG1. The invention provides a nucleotide molecule encoding the recombinant bifunctional fusion protein, an expression vector expressing the protein, a method for preparing the protein and a method for treating CD47 overexpression-related diseases. The protein belongs to a homodimer and has the molecular weight being 90 kDa.

Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

The invention relates to a method of identifying / monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand.

The invention provides extracts of brown seaweed of the genus Ascophyllum that have valuable pharmacological properties. In particular, compositions of the invention are useful for e.g.: inhibiting alpha-glucosidase activity; preventing or treating conditions mediated by alpha-glucosidase activity; reducing blood glucose levels; preventing or treating diabetes; modulating glucose uptake in adipocytes; preventing or treating obesity; scavenging free radicals; stimulating the immune system; activating macrophages; preventing or treating condition mediated by macrophage activation; and modulating nitric oxide production by macrophages. Methods for using the Ascophyllum extracts of the invention are provided, as are kits comprising Ascophyllum extracts of the invention and instructions for using the extracts.

The invention relates to application of classically activated macrophages in treatment of liver fibrosis. The invention is characterized by application of the classically activated macrophages in treatment of liver fibrosis and preparation of drugs used for treating liver fibrosis. According to the invention, matrix metalloproteinase (MMPs) molecules highly expressed in M1 macrophages and a great number of MMPs secreted by the M1 macrophages and autologous macrophages entering the liver cooperate with each other to accelerate degradation of collagen fibers and mitigate liver fibrosis, wherein autologous macrophages are raised after reinfusion of the M1 macrophages. The M1 macrophages have a good therapeutic effect on liver fibrosis, so a novel effective method is provided for clinical treatment of liver fibrosis and cirrhosis.

Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) in their lysosomes. The amount of USPIO loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal. Both fixed macrophages and activated macrophages associated with inflammatory diseases and cancer phagocytize USPIOs, and the loaded macrophages can serve to identify the extent of a macrophage-dependent disease as well as to direct treatment options. Furthermore, the absorption of energy from incident electromagnetic waves by the aggregated nanoparticles can be used for conformal thermotherapy. The USPIOs can further be used to carry drugs to the same activated macrophages. The co-administered drugs can be bound to the USPIO by condition-dependent releasing links that are responsive to local pH or heating.

Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I:These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and / or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.

The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth / regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and / or promote growth / regeneration of axons.

The invention discloses a preparation method of small-molecule panax notoginseng polysaccharide extract. The preparation method includes: using panax notoginseng as the raw material, crushing the raw material, extracting with an ethanol solution, extracting panax notoginseng residues with water obtain crude panax notoginseng polysaccharide extract, performing ethanol precipitation, dissolving precipitate with water, and then adding trifluoroacetic acid or lysozyme to perform hydrolysis to obtain crude small-molecule polysaccharide liquid; using a cation-anion exchange column to remove the protein, pigment and the like of the crude small-molecule polysaccharide liquid, using activated carbon powder for decoloring, filtering with a titanium-bar filter to obtain a colorless low-viscosity small-molecule polysaccharide solution, concentrating, and performing freeze drying to obtain the small-molecule panax notoginseng polysaccharide extract. The preparation method has the advantages that the method is simple to operate, low in cost and high in industrialization degree; the small-molecule panax notoginseng polysaccharide extract can promote macrophage proliferation, further differentiation and maturation of macrophage can be achieved to obtain activated macrophage, and the phagocytic ability of the macrophage can be evidently enhanced; fast increasing of cell immunity during a cell culture immunity test can be achieved; the extract has application prospect in immunological disease treatment, and the preparation method is suitable for industrial production.

The invention discloses dandelion tea as well as a preparation method and application thereof. The dandelion tea is prepared from the following raw materials in parts by weight: 70-85 parts of dandelions, 15-25 parts of green tea, 0.5-3 parts of liquorice roots and 0.5-3 parts of honey. The raw materials further comprise 0-2 parts of mung beans, 0-2 parts of wolfberry fruits, 0-1 parts of artemisia vulgaris, 0-2 parts of honeysuckles, 0-2 parts of wild chrysanthemum flowers and 0-2 parts of sweet-scented osmanthus. The dandelion tea disclosed by the invention adopts the formula above, and the green tea and the liquorice roots are added, so that the soup color can be changed, and the effect of the dandelion tea can also be added; and the honey is added so that the taste of the dandelion tea can be changed and the storage time can also be guaranteed. All the components are coordinated and matched, so that the dandelion tea has the effects of nourishing liver and prompting choleresis, diminishing inflammation and clearing away heat, clearing away internal heat and detoxifying, improving eyesight and removing acnes, maintaining beauty and keeping young; furthermore, the dandelions contain a plurality of types of sugars and have a relatively strong capability of activating macrophages, so that the dandelion tea has the effects of resisting tumors after being drunk for a long period, and particularly has relatively good effects on constipation and mastosis of females.

Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.

The invention discloses a naringin contained facial mask and a preparation process thereof. Naringin is added into a facial mask liquid, a main ingredient of the naringin is flavonoid and acts synergistically with nicotinamide (B3) and vitamin B6, so that the facial mask has a prominent whitening effect; when the same whitening effect is achieved, the use amount of nicotinamide is effectively reduced, and the skin allergy risk caused by the product is reduced; beta glucan which can activate macrophage and neutrophilecell is supplemented, so that the facial mask can deep remove free radical and has a radiation protection effect; meanwhile, trehalose and polyglycerol are added into the facial mask liquid and jointly act, so that the moisturizing time can be effectively prolonged; and finally, glycine, glutamic acid and proline which are mild are adopted to adjust the pH value of the facial mask liquid to 4.0-5.3, and the pH value is close to the pH value of a body fluid of a human body, so that the facial mask liquid can deep enter skin cells, and the best skin whitening and brightening effect is achieved.

The invention discloses a preparation method of an edible and medicinal fungus nanofilm. The preparation method comprises steps of slant culture, seed culture, amplification culture, and producing of a nano material. The nanofilm can be directly synthesized by microorganisms, has uniform structure, controllable appearance, and short synthesis cycle, and is applicable to expanded production. The fungus nanofilm comprises beta-glucan and chitin, wherein beta-glucan can comprehensively activate the immune system of human bodies, activate macrophage and neutrophilic granulocyte, resist diseases caused by microorganisms, and activate the nonspecific immunity of a host for curing tumours, infectious diseases and wounds, and chitin also has good antibacterial effects. The edible and medicinal fungus nanofilm has good hygroscopicity and breathability, can resist bacteria, diminish inflammation and promote wound healing, can be used as artificial skin, is degradable naturally, and has an obvious three-dimensional space net structure, so that the fungus nanofilm can be combined with drugs to be used as sustained-release materials to be applicable to fields such as health care and the like.

The invention discloses a ganoderma lucidum polysaccharide and a preparation method thereof. The method for preparing the ganoderma lucidum polysaccharide comprises the following steps: performing water extraction on ganoderma lucidum seeds, thereby obtaining extract residues; performing superfine grinding on the extract residues, thereby obtaining superfine powder; performing water extract and alcohol precipitate on the superfine powder, and collecting the precipitate, namely the ganoderma lucidum polysaccharide. The content of beta-glucosan in the ganoderma lucidum polysaccharide prepared by the invention is over 50 percent, and the ganoderma lucidum polysaccharide has obvious activity of activating macrophage.

The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexine D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.

The invention discloses a champignon beta-glucan. The main chain of the champignon beta-glucan is beta-(1->3)-D-glucan; on average, every 7-10 glucose residues on the main chain contain 2-3 (1->6) bonded glucose lateral groups; and the champignon beta-glucan is in the shape of a rod-like chain in water. The preparation method comprises the following steps: crushing the fruit body of champignon, degreasing, soaking in normal saline, centrifuging, and collecting leavings; extracting the leavings in boiling water at 100-130 DEG C, centrifuging, collecting leavings, carrying out ultrasonic extraction in pure water, and centrifuging to obtain an extracting solution; and decoloring the extracting solution, removing free proteins, dialyzing with water, concentrating, and carrying out freeze-drying to obtain the champignon beta-glucan. The champignon beta-glucan has an obvious effect of activating macrophages and a superior effect of inhibiting the release of inflammation regulation factors NO and TNF-alpha, and can be used for the preparation of medicaments or health products for improving immune function and resisting inflammation.

The invention discloses a polymer / silver active bonding compound for inhibiting the proliferation of activated macrophage, and a preparation process and applications of the bonding compound. The polymer / silver active bonding compound consists of nano elemental silver and a hydrophilic polymer modified by a target head. The polymer / silver active bonding compound is excellent in stability and can inhibit the proliferation of activated macrophage, so that the polymer / silver active bonding compound is good in anti-rheumatoid arthritis effect in vitro and in vivo.

According to the invention, a carboxylated platinum prodrug is designed and synthesized, and a coordination nano core is prepared by utilizing the coordination effect of ions and the prodrug. Lipid is wrapped outside the nano-core, and a photosensitizer is dispersed in the nano-core to construct the prodrug nano-carrier. A nano prodrug is loaded by utilizing the phagocytic function of macrophages (BMDM), so that a near-infrared light (NIR) activated macrophage-nano prodrug delivery system is prepared. The system has the characteristics of high drug loading capacity, light-operated activation and retention of self activity and functions, and efficient and synchronous drug delivery of primary tumors and metastatic tumors can be realized after intravenous injection. Meanwhile, after primary tumors are irradiated by NIR, drugs can be triggered to be released quickly, chemotherapy-photodynamic combined therapy is achieved, and the purposes of killing tumor cells and activating an immune system are achieved. Through combination of three modes of chemotherapy, photodynamic and immunization, dual treatment of primary and metastatic tumors is finally realized.

The invention discloses glycyrrhiza polysaccharide granules and a preparation method thereof; a tissue culture method is adopted to produce glycyrrhiza polysaccharide, and the glycyrrhiza polysaccharide granules can be prepared by the glycyrrhiza polysaccharide and other excipients. The glycyrrhiza polysaccharide granules comprise the components by parts: 100-150 parts of glycyrrhiza polysaccharide, 100-300 parts of sustained-release material, 100-200 parts of filler and 5-10 parts of adhesive. The glycyrrhiza polysaccharide is produced by being cultured by a fermentation tank; the developed glycyrrhiza polysaccharide granules are convenient to use and can be directly taken or taken with water; the produced glycyrrhiza polysaccharide has obvious immune dispensing activity and is capable of activating macrophage and tuberculosis (TB) lymphocyte, so that humoral immunity and cellular immunity can be enhanced, and the aims of improving the general immunity function and more effectively inhibiting tumours and acquired immunodeficiency syndrome (AIDS) can be achieved; furthermore, products developed by the polysaccharide have obvious health care function so as to have excellent develop space.